Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) manufactures and markets pharmaceuticals with a focus on diabetes treatments, including recombinant human insulin (Gansulin), insulin glargine (Pingsulin), insulin aspart (Ruisulin), insulin aspart mix 70/30 and 50/50, liraglutide injections (Tongboli), oral antidiabetics such as repaglinide tablets (Tangjierui), empagliflozin tablets (Tangjieen), sitagliptin phosphate tablets and combinations; Chinese patent medicines like Zhennaoning capsules for vascular neuropathic headache and Dongbao Gantai tablets for fatty liver; gout therapies including novel URAT1 inhibitors (THDBH130) and dual-target XO/URAT1 inhibitors (THDBH151); diabetes-related devices such as insulin pens, needles, blood glucose monitors, and patient management systems; founded in 1985 and headquartered in Tonghua, Jilin Province, China. The company operates primarily in China through subsidiaries like Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. for R&D and Tonghua Dongbao Group Import & Export Co., Ltd. for international trade, with expansion into Southeast Asia, Middle East, East Asia, South America, Africa, EU filings for insulins, and US market partnerships; it listed on the Shanghai Stock Exchange in 1994 and maintains production sites including a Biopharmaceutical Industrial Park with capacity exceeding 300 million cartridges and vials annually. Recent developments encompass Phase III initiation of semaglutide injections (THDB0225) in July 2024 via licensing with Beijing Quality Peptide Biopharmaceutical Technology Co., Ltd.; strategic cooperation with Sinopharm Group Co., Ltd. in June 2024; EMA certification of human insulin drug substance facilities for EU commercial manufacturing in July 2024 following April inspection; Category A/A1 selection for all insulin products in China's April 2024 volume-based procurement through 2027; multiple 2024 clinical milestones including Phase Ib trials for GLP-1/GIP agonist THDBH120 in diabetes and weight loss, Phase IIa for gout dual inhibitor THDBH151, Phase I completion for insulin degludec/liraglutide combination; ongoing share repurchases totaling over 3% of shares by November 2025 under plans authorized October 2025 and earlier; leadership changes appointing Li Jiahong as Chairman and Leng Chunsheng as Vice Chairman/General Manager in March 2024; Jilin Province funding for insulin degludec technology in January 2024.